TY - JOUR
T1 - Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris
AU - Shao, Shuai
AU - Chen, Jiaoling
AU - Swindell, William R.
AU - Tsoi, Lam C.
AU - Xing, Xianying
AU - Ma, Feiyang
AU - Uppala, Ranjitha
AU - Sarkar, Mrinal K.
AU - Plazyo, Olesya
AU - Billi, Allison C.
AU - Wasikowski, Rachael
AU - Smith, Kathleen M.
AU - Honore, Prisca
AU - Scott, Victoria E.
AU - Maverakis, Emanual
AU - Michelle Kahlenberg, J.
AU - Wang, Gang
AU - Ward, Nicole L.
AU - Harms, Paul W.
AU - Gudjonsson, Johann E.
N1 - Funding Information:
This study was supported by a research grant from AbbVie. This work was further supported by the National Psoriasis Foundation Psoriasis Prevention Initiative (NPF-PPI) Award (to JG, NLW, LCT, EM, and JMK); the Babcock Endowment Fund (to LCT and JEG); by NIH grants R01-AR069071 and R01-AR073196 (to JEG and NLW), P50-AR070590 and R01-AR075777 (to NLW), P30-AR075043 (to JEG), and K01-AR072129 (to LCT); and the A. Alfred Taubman Medical Research Institute (to JEG and JMK). LCT is supported by the Dermatology Foundation, Arthritis National Research Foundation, and National Psoriasis Foundation.
Publisher Copyright:
© 2021, Shao et al.
PY - 2021/10/22
Y1 - 2021/10/22
N2 - Altered epidermal differentiation along with increased keratinocyte proliferation is a characteristic feature of psoriasis and pityriasis rubra pilaris (PRP). However, despite this large degree of overlapping clinical and histologic features, the molecular signatures these skin disorders share are unknown. Using global transcriptomic profiling, we demonstrate that plaque psoriasis and PRP skin lesions have high overlap, with all differentially expressed genes in PRP relative to normal skin having complete overlap with those in psoriasis. The major common pathway shared between psoriasis and PRP involves the phospholipases PLA2G2F, PLA2G4D, and PLA2G4E, which were found to be primarily expressed in the epidermis. Gene silencing each of the 3 PLA2s led to reduction in immune responses and epidermal thickness both in vitro and in vivo in a mouse model of psoriasis, establishing their proinflammatory roles. Lipidomic analyses demonstrated that PLA2s affect mobilization of a phospholipid-eicosanoid pool, which is altered in psoriatic lesions and functions to promote immune responses in keratinocytes. Taken together, our results highlight the important role of PLA2s as regulators of epidermal barrier homeostasis and inflammation, identify PLA2s as a shared pathogenic mechanism between PRP and psoriasis, and as potential therapeutic targets for both diseases.
AB - Altered epidermal differentiation along with increased keratinocyte proliferation is a characteristic feature of psoriasis and pityriasis rubra pilaris (PRP). However, despite this large degree of overlapping clinical and histologic features, the molecular signatures these skin disorders share are unknown. Using global transcriptomic profiling, we demonstrate that plaque psoriasis and PRP skin lesions have high overlap, with all differentially expressed genes in PRP relative to normal skin having complete overlap with those in psoriasis. The major common pathway shared between psoriasis and PRP involves the phospholipases PLA2G2F, PLA2G4D, and PLA2G4E, which were found to be primarily expressed in the epidermis. Gene silencing each of the 3 PLA2s led to reduction in immune responses and epidermal thickness both in vitro and in vivo in a mouse model of psoriasis, establishing their proinflammatory roles. Lipidomic analyses demonstrated that PLA2s affect mobilization of a phospholipid-eicosanoid pool, which is altered in psoriatic lesions and functions to promote immune responses in keratinocytes. Taken together, our results highlight the important role of PLA2s as regulators of epidermal barrier homeostasis and inflammation, identify PLA2s as a shared pathogenic mechanism between PRP and psoriasis, and as potential therapeutic targets for both diseases.
UR - http://www.scopus.com/inward/record.url?scp=85117714958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117714958&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.151911
DO - 10.1172/jci.insight.151911
M3 - Article
C2 - 34491907
AN - SCOPUS:85117714958
SN - 2379-3708
VL - 6
JO - JCI Insight
JF - JCI Insight
IS - 20
M1 - :e151911
ER -